Metabolic Performance

MK-677 (ibutamoren) produces a statistically significant but modest lean-mass gain of approximately 1.6 kg above placebo over 12 months in the only controlled human trial. It simultaneously raises fasting glucose, reduces insulin sensitivity, and generated a congestive heart failure signal that terminated a separate elderly-population trial. The lean-mass benefit is real but narrow, and the cardiometabolic cost is not negligible.

Retatrutide's glucagon receptor (GCGR) component creates a dual-edged lean-mass signal: it drives hepatic amino acid catabolism via urea-cycle upregulation — a direct lean-mass liability — while simultaneously increasing energy expenditure through fat oxidation, reducing substrate pressure on muscle protein. Resistance training resolves this tension by redirecting circulating amino acids toward myofibrillar synthesis rather than hepatic gluconeogenesis.

Mostly animal data, with one narrow human exception. A 2026 UCLA Health review of 565 studies across six unapproved peptides concluded that human evidence is sparse and marketing claims substantially outpace the clinical record. MK-677 has the strongest human dataset, but its one meaningful RCT enrolled elderly adults rather than athletes, and total fat mass rose alongside lean-mass gains.

A 2025 meta-analysis by Hays et al found that TRE combined with exercise produced a significant fat-mass reduction and improved HOMA-IR versus exercise-matched controls, while fat-free mass remained statistically unchanged. The benefit is real but modest in absolute terms, and protein intake is the primary moderating variable.

Acute endurance exercise reliably elevates circulating humanin and MOTS-c within minutes of exertion; resistance exercise does not produce the same acute plasma response. Across pooled human studies, exercise-driven MOTS-c rises co-occur with AMPK activation, improved GLUT4 translocation, and reduced HOMA-IR, while humanin increases correlate with attenuated oxidative stress markers — providing a mechanistic bridge between training load and insulin-sensitivity gains.

No controlled trial has directly tested retatrutide combined with resistance training and high protein intake. Mechanistic evidence indicates that mechanical loading and leucine-triggered mTORC1 activation operate through pathways additive to retatrutide's triple-receptor pharmacology. The 2025 Coskun body-composition sub-study reported 35.4% of weight lost as lean tissue without exercise or protein controls.

Yes — GLP-1-driven gastric emptying delay and appetite suppression create a protein delivery problem that a simple gram-per-kilogram target cannot solve. The roughly 36-minute solid-food emptying delay documented by Hiramoto et al. (2024) blunts postprandial aminoacidemia precisely when post-exercise mTORC1 sensitivity is highest, requiring faster-absorbing protein forms, pre-exercise loading, and deliberate leucine co-dosing.

Yes — with caveats. Across Phase III RCTs and a 2026 meta-analysis, tesamorelin reduced visceral adipose tissue by 15–20% over 26 weeks without significantly shifting mean fasting insulin, fasting glucose, or HbA1c. Training recovery data remain indirect: pulsatile GH and elevated IGF-1 support protein synthesis, but no controlled exercise-plus-tesamorelin RCT has reported post-exercise recovery endpoints in non-HIV metabolically active adults.

Yes — combining GLP-1 receptor agonist therapy with structured resistance training produces superior fat mass reduction and insulin sensitivity improvement versus GLP-1 monotherapy. A 2026 network meta-analysis across nine RCTs ranked the combination first on weight (SMD −1.04), fat mass, and HOMA-IR, with the exercise arm adding a statistically significant HOMA-IR benefit (SMD −0.28) that pharmacotherapy alone did not achieve.

Current evidence sets the functional floor at 1·2 g per kilogram of total body weight per day during active GLP-1 cut phases. The 2025 AJCN joint advisory refines this to 1·5 g/kg of fat-free mass per day. Observed intake in GLP-1 users averages just 0·6 g/kg/day, directly explaining the 25–39% lean-mass fraction of total weight lost on semaglutide and tirzepatide.

Precision nutrition — the systematic calibration of protein quality, micronutrient density, meal timing, and dietary pattern to an individual's metabolic phenotype — measurably shifts lean mass outcomes during GLP-1 receptor agonist therapy. Structured nutritional intervention can reduce the lean-mass fraction of total weight lost from roughly 25–40% to below 15%, according to a 2025 review.

Yes — current comparative data show tirzepatide produces larger absolute and proportional fat-mass reductions than semaglutide. DXA sub-studies indicate approximately 83 percent of weight lost as fat versus 60 to 70 percent for semaglutide. Tirzepatide also generates greater suppression of uncontrolled eating and high-fat food cravings, attributable to GIP receptor co-agonism acting on hypothalamic reward circuitry.